139 related articles for article (PubMed ID: 18641930)
1. [Multimodal therapy of prostate cancer - 2 case reports].
Lamche M; Bauer WA; Schramek P
Wien Med Wochenschr; 2008; 158(11-12):303-6. PubMed ID: 18641930
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of biochemical bone metabolism parameters].
Hegele A; Olbert P; Wahl HG; Hofmann R
Urologe A; 2007 Sep; 46(9):1285-6. PubMed ID: 17609924
[No Abstract] [Full Text] [Related]
3. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
4. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
5. Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: a case report.
von Eyben FE; Kangasmäki A; Kiljunen T; Joensuu T
Tumori; 2013; 99(3):e120-3. PubMed ID: 24158080
[TBL] [Abstract][Full Text] [Related]
6. [Extended salvage pelvic and retroperitoneal lymph node dissection due to prostate cancer relapse].
Osmonov DK; Aksenov AV; Jünemann KP
Aktuelle Urol; 2013 Jan; 44(1):50-2. PubMed ID: 23325670
[TBL] [Abstract][Full Text] [Related]
7. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
8. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
9. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Messing EM
J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14532828
[No Abstract] [Full Text] [Related]
10. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Rogers C
J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14575038
[No Abstract] [Full Text] [Related]
11. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
12. [Systemic treatment of metastatic prostate cancer].
Wörmann B; Wolff JM
Urologe A; 2010 Feb; 49(2):221-7. PubMed ID: 20180063
[TBL] [Abstract][Full Text] [Related]
13. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy.
Cheng CW; Bergstralh EJ; Zincke H
Cancer; 1993 Feb; 71(3 Suppl):996-1004. PubMed ID: 7679047
[TBL] [Abstract][Full Text] [Related]
14. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P; Steurer S; Huland H; Graefen M
J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
[No Abstract] [Full Text] [Related]
15. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy.
Tilki D; Mandel P; Seeliger F; Kretschmer A; Karl A; Ergün S; Seitz M; Stief CG
J Urol; 2015 Feb; 193(2):484-90. PubMed ID: 25180792
[TBL] [Abstract][Full Text] [Related]
16. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
17. [Salvage lymph node dissection in radical prostatectomy failure - a case study].
Marečková N; Staník M; Macík D; Doležel J
Rozhl Chir; 2017; 96(6):260-262. PubMed ID: 28931292
[TBL] [Abstract][Full Text] [Related]
18. [Current treatment of locally advanced and metastatic prostate cancer].
Ponholzer A; Steinbacher F; Madersbacher S; Schramek P
Wien Med Wochenschr; 2011 Aug; 161(15-16):377-81. PubMed ID: 21953428
[TBL] [Abstract][Full Text] [Related]
19. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
20. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
